Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414086 · ClinicalTrials.gov registry record
Predictor of Clinical Response to Acthar in Myositis
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 20
- Enrollment target
NCT03414086: Completed study, sponsored by University of Pittsburgh.
NCT03414086 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03414086 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Comparing the clinical effects of Acthar Gel before and after treatment and compare it to patients with inactive disease.
Primary Outcome
The International Myositis Assessment \& Clinical Studies (IMACS) definition of improvement: Three of any of the six core set measures improved by greater than or equal to twenty percent, with no more than two core set measuring by greater than or equal to twenty five percent.
Interventions
- OTHER Healthy Control
- OTHER Myositis in Remission
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2022-07-30 |
What the finished NCT03414086 record still lists
NCT03414086 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Healthy Control is the first listed.
NCT03414086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03414086 about?
NCT03414086 is a clinical study titled "Predictor of Clinical Response to Acthar in Myositis". Comparing the clinical effects of Acthar Gel before and after treatment and compare it to patients with inactive disease.
What is the current status of trial NCT03414086?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-11-06. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT03414086?
The interventions under investigation include: Healthy Control (OTHER), Myositis in Remission (OTHER).
Who is sponsoring clinical trial NCT03414086?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI